Currently being developed to treat Lupus, P140 potentially has a far wider and more fundamental application as an ‘immunormaliser’.Read More

You might also be interested in reading Alphabet GAAP EPS of $2.31 beats by $0.12, revenue of $96.43B beats by $2.45B.